Telesis Bio announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA enzymatic DNA synthesis, EDS, platform. Going forward, the company will increasingly concentrate its efforts on expanding the adoption of Gibson SOLA for both DNA and mRNA high throughput drug discovery applications and will specifically target the BioXp automation platform on mRNA synthesis, where the Company believes it has a highly differentiated offering with significant advantages over existing solutions. The Company believes that its Gibson SOLA platform is easily integrated onto many third-party automation platforms as well as the Company’s own BioXp system, and enables the synthesis of high-fidelity synthetic oligonucleotides, genes, and transfection-ready mRNA at a wide range of scales as quickly as overnight. “We believe our advances in enzymatic synthesis will ultimately accelerate the current drug discovery paradigm by creating mRNA-based vaccine and therapeutic candidates in days rather than weeks or months,” said Dan Gibson, PhD, Co-Founder of Telesis Bio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBIO:
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
- TBIO Earnings this Week: How Will it Perform?
- Biotech Alert: Searches spiking for these stocks today
- Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
- Telesis Bio sees Q4 revenue $7M vs. $9.5M last year